Thirty Madison launches direct-to-consumer health brand for allergies
Thirty Madison launched a new telehealth brand for people with seasonal allergies. It’s the latest addition to the company’s growing list of direct-to-consumer brands, which include hair loss, migraines and acid reflux.
Shares0
Thirty Madison, the company behind a growing string of direct-to-consumer health brands, is moving into allergies. Its newest brand, called Picnic, lets users order allergy medications delivered to their homes on a subscription basis.
The company is specifically focused on treatments for allergic rhinitis or seasonal allergies not food allergies. Most of the treatments it offers are over-the-counter, such as the generic versions of Benadryl, Zyrtec and Flonase. It also sells a few prescription medications, which require a virtual consultation with a physician, including oral antihistamines, prescription nasal sprays and eye drops.
Athenex’s bid to offer an oral version of an intravenous chemotherapy has stalled after the FDA rejected the drug. Among the remedies proposed by the regulator is another Phase 3 study.
Joe Muldoon
Joe Muldoon is CEO of FAST BioMedical. Muldoon has over 30 years of experience working with innovative companies. A serial entrepreneur, Muldoon has served as an advisor, investor, President and CEO, and Board Director to over 35 entrepreneurially driven organizations. Previously, he was an Entrepreneur in Residence at the Indiana Venture Center and President and CEO of FirstMile Technologies. Prior to that, he served as President of Brightpoint North America, a publicly-traded Fortune 500 company that grew to $750M under his leadership, sold to Ingram-Micro. Muldoon started his career as an E&Y trained CPA, where he was a manager in Entrepreneurial Services. Joe sits on several boards, is a frequent speaker and panelist for IU MBA programs, and regularly advises early-stage companies.
Share /
Mar 2, 2021 at 8:05 AM
Promoted
In a podcast with MedCity News, Cho talked about the company’s profile in the San Diego life science ecosystem, the need to fail fast and frequently in the early stages of drug development and the work BMS is doing to combat Covid-19.
MedCity News
Novavax preps to meet global demand, plans capacity for 2B Covid vaccine doses
Novavax says it’s building up its manufacturing capacity now to be ready to ship Covid-19 vaccine globally as emergency authorizations are granted in coming months. The company expects to seek FDA authorization in the second quarter.
Shares1
With three Covid-19 vaccines now authorized by the FDA, focus is now turning to manufacturing capacity. As Novavax prepares to add its vaccine to the mix, it is gearing up to meet global demand with the projected capability of producing about 2 billion vaccine doses by the middle of this year.